AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beryl Drugs Ltd reported audited financial results for FY2026 with revenue from operations declining to Rs 1931.02 lakhs from Rs 2255.48 lakhs in FY2025, a drop of about 14.4%. Net profit after tax fell to Rs 42.48 lakhs from Rs 56.75 lakhs in the previous year. The decline was primarily due to a manufacturing stop order issued by the Food and Drugs Administration, Madhya Pradesh in January 2025 for the Blow Fill Seal (BFS) section, which suspended production until November 2025. The company adopted Ind AS 116 (Leases) effective April 2024, recognizing a right-of-use asset of Rs 27.75 lakhs and lease liability of Rs 4.95 lakhs. The auditors issued an unmodified (clean) opinion but included three emphasis of matter notes regarding unrecorded professional tax liability, the BFS manufacturing suspension, and the lease accounting change.
The revenue and profit decline due to the temporary manufacturing shutdown is negative for shareholders, though the stop order was later revoked. The unrecorded professional tax liability and clean audit opinion without qualifications provide some stability. The company remains operational with positive cash flows from operations of Rs 364.95 lakhs.